The Life Sciences industry has excited the world by leveraging new platforms to address some of society’s most pressing health problems. But the industry is also facing an innovation deficit that requires an ecosystem mindset to find new avenues for growth in particular, as specialty drug spending far outpaces traditional drug spending. New modalities that have emerged include gene and cell therapies, mRNA drugs or vaccines, and complex biologics.
At the same time, costs of capital are increasing, leading an industry that has focused on topline growth to address costs, and strengthen financial and operational resilience. All of this, as digital disrupts operating models and how care is delivered, while regulatory considerations transform pharmaceutical supply chains.
EY-Parthenon Health and Wellness Strategy Consulting teams cover a broad spectrum of life science services for both corporate and private equity clients, including biopharma (branded and generics), medical technology, life science services (CRO and CDMO), diagnostics, life science tools and reagents. Through corporate and growth strategy services, we provide in-depth, real-world perspectives and identify inorganic growth options that lead to M&A programs. Through commercial due diligence services, we help create heavily researched, data-backed insights for our clients. We also help you develop and implement innovation strategies around digital capabilities and emerging technologies.